Results from the WHO external quality assessment for the respiratory syncytial virus pilot, 2016-17

Show simple item record Jackson, Sandra Peret, Teresa C. T. Ziegler, Thedi T. Thornburg, Natalie J. Besselaar, Terry G. Broor, Shobha Barr, Ian Baumeister, Elsa Chadha, Mandeep Chittaganpitch, Malinee Darmaa, Badarch Ellis, Joanna Fasce, Rodrigo Fasce, Rodrigo Herring, Belinda Herve, Kadjo Hirve, Siddhivinayak Li, Yan Pisareva, Maria Moen, Ann Naguib, Amel Palekar, Rakhee Potdar, Varsha Siqueira, Marilda Treurnicht, Florette Tivane, Almiro Venter, Marietjie Wairagkar, Niteen Zambon, Maria Zhang, Wenqing 2020-10-22T07:45:52Z 2020-10-22T07:45:52Z 2020
dc.description.abstract BACKGROUND : External quality assessments (EQAs) for the molecular detection of respiratory syncytial virus (RSV) are necessary to ensure the provision of reliable and accurate results. One of the objectives of the pilot of the World Health Organization (WHO) Global RSV Surveillance, 2016-2017, was to evaluate and standardize RSV molecular tests used by participating countries. This paper describes the first WHO RSV EQA for the molecular detection of RSV. METHODS : The WHO implemented the pilot of Global RSV Surveillance based on the WHO Global Influenza Surveillance and Response System (GISRS) from 2016 to 2018 in 14 countries. To ensure standardization of tests, 13 participating laboratories were required to complete a 12 panel RSV EQA prepared and distributed by the Centers for Disease Control and Prevention (CDC), USA. The 14th laboratory joined the pilot late and participated in a separate EQA. Laboratories evaluated a RSV rRT-PCR assay developed by CDC and compared where applicable, other Laboratory Developed Tests (LDTs) or commercial assays already in use at their laboratories. RESULTS : Laboratories performed well using the CDC RSV rRT-PCR in comparison with LDTs and commercial assays. Using the CDC assay, 11 of 13 laboratories reported correct results. Two laboratories each reported one false-positive finding. Of the laboratories using LDTs or commercial assays, results as assessed by Ct values were 100% correct for 1/5 (20%). With corrective actions, all laboratories achieved satisfactory outputs. CONCLUSIONS : These findings indicate that reliable results can be expected from this pilot. Continued participation in EQAs for the molecular detection of RSV is recommended. en_ZA
dc.description.department Medical Virology en_ZA
dc.description.librarian am2020 en_ZA
dc.description.sponsorship The Bill and Melinda Gates Foundation, the Respiratory Viruses Branch, Division of Viral Diseases, CDC, Atlanta, and the CDC International Reagent Resource (IRR), USA. en_ZA
dc.description.uri en_ZA
dc.identifier.citation Jackson, S., Peret, T.C.T., Ziegler, T.T., et al. Results from the WHO external quality assessment for the respiratory syncytial virus pilot, 2016-17. Influenza and or Respiratory Viruses 2020;00:1–7. 10.1111/irv.12771. NYP. en_ZA
dc.identifier.issn 1750-2640 (print)
dc.identifier.issn 1750-2659 (online)
dc.identifier.other 10.1111/irv.12771
dc.language.iso en en_ZA
dc.publisher Wiley Open Access en_ZA
dc.rights © 2020 The Authors. This is an open access article under the terms of the Creative Commons Attribution License. en_ZA
dc.subject External quality assessment (EQA) en_ZA
dc.subject Respiratory syncytial virus (RSV) en_ZA
dc.subject Polymerase chain reaction (PCR) en_ZA
dc.title Results from the WHO external quality assessment for the respiratory syncytial virus pilot, 2016-17 en_ZA
dc.type Article en_ZA

Files in this item

This item appears in the following Collection(s)

Show simple item record